CRSP Logo

CRISPR Therapeutics AG (CRSP) 

NASDAQ
Market Cap
$3.93B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
502 of 774
Rank in Industry
270 of 432

Largest Insider Buys in Sector

CRSP Stock Price History Chart

CRSP Stock Performance

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product …

Insider Activity of CRISPR Therapeutics AG

Over the last 12 months, insiders at CRISPR Therapeutics AG have bought $0 and sold $12.94M worth of CRISPR Therapeutics AG stock.

On average, over the past 5 years, insiders at CRISPR Therapeutics AG have bought $0 and sold $48.8M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 54,922 shares for transaction amount of $1.37M was made by Vertex Pharmaceuticals (Europe) Ltd (10 percent owner) on 2018‑12‑27.

List of Insider Buy and Sell Transactions, CRISPR Therapeutics AG

2024-11-11SaleChief Executive Officer
30,000
0.0356%
$55.62$1.67M-11.55%
2024-10-14SaleChief Executive Officer
4,293
0.005%
$46.28$198,680+2.38%
2024-10-14SaleGeneral Counsel and Secretary
1,089
0.0013%
$46.28$50,399+2.38%
2024-06-21SaleChief Operating Officer
3,366
0.0036%
$56.09$188,799-14.14%
2024-04-15SaleChief Executive Officer
19,582
0.0235%
$59.91$1.17M-11.84%
2024-03-15SaleChief Executive Officer
20,000
0.0236%
$72.48$1.45M-25.55%
2024-03-15SaleChief Financial Officer
3,524
0.0042%
$72.69$256,160-25.55%
2024-03-12SaleChief Executive Officer
4,583
0.0054%
$74.44$341,159-27.29%
2024-03-12SaleGeneral Counsel and Secretary
1,146
0.0013%
$74.44$85,308-27.29%
2024-03-11SaleChief Executive Officer
9,802
0.0119%
$78.26$767,105-28.67%
2024-03-11SaleGeneral Counsel and Secretary
2,801
0.0034%
$78.26$219,206-28.67%
2024-02-20SaleChief Executive Officer
6,370
0.0081%
$79.67$507,498-29.67%
2024-02-20SaleGeneral Counsel and Secretary
1,913
0.0024%
$79.67$152,409-29.67%
2024-02-15SaleChief Executive Officer
20,000
0.0256%
$80.36$1.61M-34.29%
2024-01-29SaleChief Executive Officer
50,000
0.0582%
$60.51$3.03M-14.86%
2024-01-16SaleChief Executive Officer
20,000
0.0249%
$62.50$1.25M-11.24%
2023-05-30SaleChief Executive Officer
25,000
0.0319%
$64.88$1.62M-11.56%
2023-04-25SaleChief Executive Officer
25,000
0.033%
$50.67$1.27M+19.36%
2023-03-29SaleChief Executive Officer
25,000
0.0316%
$44.46$1.11M+27.58%
2023-02-27SaleChief Executive Officer
25,000
0.0316%
$48.25$1.21M+13.52%

Insider Historical Profitability

47.06%
BAYER AKTIENGESELLSCHAFT10 percent owner
5632802
6.5994%
$46.1010+77.06%
Vertex Pharmaceuticals (Europe) Ltd10 percent owner
5380940
6.3043%
$46.1040+63.29%
CELGENE CORP /DE/10 percent owner
4173019
4.8891%
$46.10121+31.44%
GLAXOSMITHKLINE PLC10 percent owner
3220627
3.7733%
$46.1010+31.44%
George Simeondirector
3220627
3.7733%
$46.1010+31.44%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ARK Investment Management LLC$555.98M9.618.16M-4.44%-$25.84M1.92
Capital International Investors$534.17M9.237.84M+27.75%+$116.05M0.11
Sumitomo Mitsui Trust Holdings$222.8M3.853.27M-3%-$6.88M0.15
Nikko Asset Management Americas Inc$222.7M3.853.27M-3%-$6.88M1.67
T Rowe Price Investment Management Inc$184.33M3.192.7M-25.11%-$61.81M0.11
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.